Berenberg lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps a Hold rating on the shares. The firm thinks BioNTech’s ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee reports from Nvidia and Walmart this week. So far, the Q3 ea ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee reports from Nvidia and Walmart this week. So far, the Q3 ea ...

After a generation of stagnation, interest in U.S. nuclear energy is sky high, thanks to artificial intelligence’s voracious ...

The post Market Analysis: November 17th, 2025 appeared first on Stock Target Advisor.

Since May 2025, Pfizer (PFE) traded in a narrow range between $24.00 and $26. The company does not have shareholder ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else ...

Jeffrey Gundlach, CEO of DoubleLine Capital, warned in a podcast appearance Monday that private credit "has the same ...

Economic cost of L.A. wildfires expected to keep rising, Bezos suffers rocket launch setback in space race with Musk, more news to start your day. The Edge specializes in special situations such as ...

The healthcare sector is heterogeneous, with a wide dispersion in returns between the best- and worst-performing stocks. Active management can pay off. Occidental rises ahead of earnings, Delta sinks ...

This doesn’t mean an outright rejection of all premium products; rather, it signifies a re-evaluation of perceived value and ...